Grove Neurology is currently enrolling patients in the following studies:
Alzheimer’s Disease Research:
Alzheimer’s disease affects more than 6 million Americans and remains one of the leading causes of disability in older adults. While current treatments can ease symptoms, they do not stop the disease. Our clinical trials aim to change that by focusing on earlier detection, prevention, and potential disease-modifying therapies.
We are actively enrolling in multiple clinical trials focused on the early detection, prevention, and treatment of Alzheimer’s disease. Our current studies include options for individuals who:
- Are experiencing early signs of memory loss or have been recently diagnosed,
- Have a family history of Alzheimer’s or are at higher risk, or
- Are cognitively healthy but wish to contribute to research aimed at earlier diagnosis.
These studies are designed to evaluate a variety of investigational approaches, including:
- Potential disease-modifying medications aimed at slowing progression in the earliest stages
- Digital and imaging-based tools to detect brain changes before symptoms begin
- Non-invasive interventions that may help preserve memory and function.
Currently Enrolling Studies:
F. Hoffmann-La Roche Ltd - Protocol WP45722 (TRAVELLER):
A global master pre-screening study designed to identify individuals with early signs of Alzheimer’s disease through blood-based biomarkers (pTau217) and cognitive testing, determining their eligibility for future Roche interventional trials.
F. Hoffmann-La Roche Ltd - Protocol WN45447 (TRONTINEMAB):
A Phase II randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trontinemab, an anti-amyloid beta monoclonal antibody with blood-brain barrier penetration, in participants with prodromal to mild Alzheimer's disease.
GAP Innovations - Protocol Bio-Hermes-002:
An international, multi-device diagnostic study designed to evaluate and compare novel blood-based and digital biomarkers for Alzheimer’s disease against gold standard diagnostics (PET and CSF), with an emphasis on recruitment of diverse populations.
IGC Pharma, Inc. – Protocol IGC-AD1-P2BIDAG:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of IGC-AD1 in Participants With Agitation in Dementia Due to Alzheimer’s Disease
This trial is evaluating IGC-AD1, an investigational oral solution containing low-dose THC and melatonin, designed to help reduce agitation in individuals with Alzheimer’s disease dementia. Agitation can significantly impact quality of life for both patients and caregivers, and treatment options remain limited. The goal of this study is to determine whether IGC-AD1 can safely reduce the severity and frequency of agitation compared with placebo. Researchers will assess changes in agitation, behavior, cognitive function, and caregiver burden over the course of the study. All participants will be closely monitored through regular clinical evaluations, safety assessments, and standardized behavioral scales throughout the trial.
Parkinson’s Disease Research
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s, affecting nearly one million people in the U.S. It is progressive, and while symptoms can be managed, there are currently no approved treatments that slow or stop the disease. Our research targets this unmet need.
We are currently enrolling participants in clinical trials focused on individuals who:
- Have been diagnosed with Parkinson’s disease at any stage
- Are experiencing symptoms such as tremors, stiffness, balance issues, or slowness, even without a formal diagnosis
- Have been living with Parkinson’s for several years and are interested in contributing to research
- Want access to investigational therapies not yet available to the public
Currently Enrolling Study:
Biohaven Therapeutics Ltd – Protocol BHV8000-301:
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease
This trial is evaluating BHV-8000, an oral medication that targets immune system pathways involved in neuroinflammation. The goal is to determine whether this drug can delay disease progression by modulating the JAK1/TYK2 signaling pathways. Participants are followed over 48 weeks, and those who complete the study may be eligible for an open-label extension.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Research
CIDP is a rare autoimmune disorder that targets the nerves, leading to weakness, numbness, fatigue, and loss of reflexes. It often requires long-term treatment and close monitoring. While IVIG infusions have become a standard therapy, newer options are being developed to improve how treatment is delivered and how well it works over time. Our research focuses on expanding those options.
We are currently enrolling individuals who:
- Have been diagnosed with CIDP
- Are experiencing symptoms such as muscle weakness, sensory loss, or fatigue
- Are looking for more convenient or innovative alternatives to their current treatment plan
Currently Enrolling Studies:
Argenx BV – Protocol ARGX-117-2401
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ARGX-117 in Adults With CIDP
This trial is evaluating ARGX-117, an investigational medication that targets part of the immune system believed to be involved in nerve damage. Participants will be transitioned off IVIG or corticosteroids and monitored to assess whether ARGX-117 can maintain disease control without the need for ongoing infusions.
Argenx BV – Protocol ARGX-117-2402:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This trial is evaluating empasiprubart, an investigational intravenous medication designed to target part of the immune system known as the complement pathway, which is believed to play a role in nerve damage in CIDP. The goal of the study is to determine whether empasiprubart can improve functional ability and reduce disability compared with placebo in adults with active CIDP. Researchers will assess changes in strength, mobility, daily function, and overall quality of life. All participants will be closely monitored through regular clinical evaluations, safety labs, and functional assessments throughout the study.
Takeda Pharmaceuticals – Protocol TAK-411-2001
A Phase 4, Open-label, Multicenter Study to Evaluate the Effectiveness and Safety of Intravenous Immune Globulin (IVIG, Gammaplex®) in Subjects With CIDP Transitioning to Home Infusion
This study, sponsored by Takeda, is evaluating how safe and effective it is for patients with CIDP to receive their IVIG infusions at home instead of in a clinic. It focuses on quality of life, patient satisfaction, and symptom control during the transition to home-based care.
Myasthenia Gravis (MG) Research
Myasthenia gravis is a chronic autoimmune disorder that disrupts the connection between nerves and muscles, leading to symptoms like drooping eyelids, difficulty swallowing, blurred vision, and overall muscle weakness. While treatments exist, many patients continue to experience flares or side effects. Our research is focused on evaluating new therapies that may work faster, last longer, or come with fewer trade-offs.
We are currently enrolling individuals who:
- Have been diagnosed with generalized myasthenia gravis (gMG)
- Are still experiencing symptoms despite current treatment
- Are looking for alternative or more convenient treatment options
- Are interested in contributing to the future of MG care and research
Currently Enrolling Study:
Argenx BV – Protocol ARGX-113-2407:
A Phase 4, Open-Label, Prospective Study to Evaluate Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-Onset gMG
This trial is studying how patients newly diagnosed with gMG respond to efgartigimod PH20 SC, an under-the-skin injection that targets key parts of the immune system involved in MG. The goal is to assess symptom improvement, quality of life, and how this therapy performs in real-world settings when used as a first-line treatment.
Argenx BV – Protocol ARGX-999-2-MG-2000:
A Phase 2a, Multicenter, Exploratory Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Investigational Regimens in Participants With Myasthenia Gravis
This platform trial is designed to evaluate multiple investigational treatment regimens in adults with myasthenia gravis. The study uses a master protocol structure that allows different therapies to be studied over time under one unified framework. The goal is to assess safety, tolerability, and early signs of clinical benefit using standardized myasthenia gravis outcome measures, including symptom severity and functional status assessments. Participants will undergo regular neurological evaluations, laboratory testing, and safety monitoring throughout the study to ensure close oversight and careful assessment of treatment response.
Multiple Sclerosis (MS) Research
Multiple sclerosis is a chronic condition that affects the central nervous system, often causing symptoms like fatigue, vision problems, numbness, and mobility issues. At Visionary Investigators Network, we’re focused on research that may help people with relapsing forms of MS reduce flare-ups, slow disability progression, and improve day-to-day function. Our clinical trials explore next-generation therapies that target inflammation and provide better disease control—with fewer side effects and more convenient dosing.
We are currently enrolling individuals who:
- Have been diagnosed with relapsing MS (RMS)
- Are open to trying an investigational medication as part of a research study
Want to contribute to the future of MS care and innovation
Currently Enrolling Study:
Novartis Pharmaceuticals – Protocol CLOU064C12302:
A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of Remibrutinib Compared With Teriflunomide in Participants With Relapsing Multiple Sclerosis
This trial is testing Remibrutinib, an oral medication that targets the immune system to reduce inflammation in the brain and spinal cord. The goal is to determine whether Remibrutinib can reduce relapse rates, slow progression of disability, and offer a more convenient alternative to current therapies. All participants will be closely monitored through regular exams, labs, and imaging.
Epilepsy & Focal Seizures Research
Focal epilepsy is a form of seizure disorder that begins in one area of the brain and can impact memory, awareness, movement, and quality of life. At Visionary Investigators Network, we’re focused on clinical research that may help people living with focal seizures gain better seizure control, experience fewer side effects, and improve day-to-day function. Our studies explore investigational therapies designed to work alongside existing medications for people whose seizures remain uncontrolled.
We are currently enrolling individuals who:
- Have been diagnosed with focal (partial-onset) epilepsy
- Continue to have seizures despite taking antiseizure medications
- Are open to trying a new investigational therapy in addition to their current treatment
Currently Enrolling Study:
Praxis Precision Medicines – Protocol PRAX-628-322:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vormatrigine in Adults With Focal Onset Seizures
This trial is evaluating vormatrigine, an investigational once-daily oral medication designed to selectively target sodium channels involved in abnormal electrical activity in the brain. The goal of the study is to determine whether vormatrigine can reduce seizure frequency and improve seizure control in adults with focal epilepsy who continue to experience seizures despite taking one to three antiseizure medications. Participants will remain on their stable background therapy while receiving study treatment. Researchers will assess changes in seizure frequency, safety, and tolerability throughout the trial. All participants will be closely monitored through regular clinical visits, neurological evaluations, laboratory testing, ECGs, and safety assessments during the study.
Supernus Pharmaceuticals – Protocol 817P202:
A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of SPN-817 (Huperzine A) as Adjunctive Therapy in Adults With Treatment-Resistant Epilepsy
This study is evaluating SPN-817 (huperzine A), an investigational oral therapy designed to modulate neurotransmitter activity in the brain, as an add-on treatment for adults with treatment-resistant epilepsy, including individuals with seizures associated with focal cortical dysplasia. The goal of the study is to assess the safety and tolerability of SPN-817 while also evaluating its potential to reduce seizure frequency when used alongside stable background antiseizure medications. Researchers will measure changes in seizure frequency, responder rates, and quality of life throughout the study. All participants will be closely monitored through regular clinical visits, seizure diary tracking, laboratory testing, and safety assessments during treatment.
